Subject: Hear All About HLTY and Their COVID-19 Response

SCV Client Spotlight
BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement., Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence.
Facebook Twitter YouTube
PreCheck Health Services, Inc. (Pink Sheets: HLTY) as the distributor of Co-Diagnostics’ (Nasdaq: CODX) Logix Smart™ COVID-19 test in Panama, Ecuador and Russia.
Hot Stock to WatchHot Stock to Watch

Company: PreCheck Health Services, Inc. (Pink Sheets: HLTY)


Price: 0.40

Change (%): + 0.02 (5.26)

Volume: 25,793
HLTY Chart

Justin Anderson, CEO of PreCheck Health Services, Inc. is Featured in a New Interview at

AUSTIN, Texas, March 18, 2020 (GLOBE NEWSWIRE) - Inc. and PreCheck Health Services, Inc. (Pink Sheets: HLTY) (the “Company”), a provider of medical screening devices which provide data to assist physicians in preventing and treating chronic diseases, announced today that Justin Anderson is featured in an exclusive new audio interview at

The interview can be heard at:

Justin Anderson, CEO of PreCheck Health Services, Inc., called into, Inc. to go over his efforts since taking the helm as CEO in December 2019, his company’s recent news with PreCheck as the distributor of Co-Diagnostics’ (Nasdaq: CODX) Logix Smart™ COVID-19 test in Panama, Ecuador and Russia, and what is next for his Company in the global response to coronavirus.

In addition, Anderson touched on the other markets and revenue streams for HLTY. With the purchase of JAS Consulting, a provider of healthcare management, billing, and coding services, and PreCheck’s PC8B, an FDA-cleared and patented medical screening device, the company is evolving into a vertically integrated player in the healthcare markets. PreCheck’s PC8B can screen for multiple risk factors underlying certain chronic ailments, such as insulin resistance, cardiovascular disease (including PAD), endothelia dysfunction, digestive problems, and fatigue. The PC8B’s software helps the physician recommend a treatment plan for the patient.

Continue Reading

SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks